DIVIS LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of DIVIS LABORATORIES have increased by 1.00% YoY .
The Earnings Per Share (EPS) of DIVIS LABORATORIES has decreased by -12.28 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
DIVIS LABORATORIES Last 5 Annual Financial Results
[BOM: 532488|NSE : DIVISLAB]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹7,845 Cr | ₹7,767 Cr | ₹8,960 Cr | ₹6,969 Cr | ₹5,394 Cr |
| Expenses | ₹5,639 Cr | ₹5,398 Cr | ₹5,079 Cr | ₹4,108 Cr | ₹3,571 Cr |
| Operating Profit (Excl OI) | ₹2,206 Cr | ₹2,369 Cr | ₹3,881 Cr | ₹2,861 Cr | ₹1,823 Cr |
| Other Income | ₹339 Cr | ₹345 Cr | ₹116 Cr | ₹63 Cr | ₹190 Cr |
| Interest | ₹4.00 Cr | ₹2.00 Cr | ₹2.00 Cr | ₹2.10 Cr | ₹7.14 Cr |
| Depreciation | ₹378 Cr | ₹343 Cr | ₹312 Cr | ₹256 Cr | ₹186 Cr |
| Profit Before Tax | ₹2,163 Cr | ₹2,369 Cr | ₹3,684 Cr | ₹2,666 Cr | ₹1,819 Cr |
| Profit After Tax | ₹1,600 Cr | ₹1,824 Cr | ₹2,960 Cr | ₹1,984 Cr | ₹1,377 Cr |
| Consolidated Net Profit | ₹1,600 Cr | ₹1,824 Cr | ₹2,960 Cr | ₹1,984 Cr | ₹1,377 Cr |
| Earnings Per Share (Rs) | ₹60.38 | ₹68.83 | ₹111.53 | ₹74.75 | ₹51.86 |
| PAT Margin (%) | 20.28 | 23.33 | 32.94 | 28.38 | 25.23 |
| ROE(%) | 12.15 | 14.89 | 28.16 | 23.90 | 19.30 |
| ROCE(%) | 16.46 | 19.36 | 35.06 | 32.07 | 25.36 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 181,418.8 Cr |
| Revenue (TTM) | : | ₹ 9,360.0 Cr |
| Net Profit(TTM) | : | ₹ 2,191.0 Cr |
| EPS (TTM) | : | ₹ 82.5 |
| P/E (TTM) | : | 82.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| DIVIS LABORATORIES | -0.7% | 1.6% | 50.2% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.4% | -0.9% | 4.8% |
| CIPLA | -1.7% | -1.1% | -2.3% |
| TORRENT PHARMACEUTICALS | -1.1% | 1.6% | 13.7% |
| DR REDDYS LABORATORIES | -4.3% | -8% | -4.4% |
| MANKIND PHARMA | 6.8% | 8% | 20.9% |
| ZYDUS LIFESCIENCES | -1.9% | 0.1% | -16.5% |
| LUPIN | -4.3% | -6.4% | 4.6% |
| AUROBINDO PHARMA | -5.1% | -2.7% | -15.3% |
DIVIS LABORATORIES Revenues
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | 1.00 % |
| 5 Yr CAGR | 9.82 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹7,845 Cr | 1.00 | |
| Mar2023 | ₹7,767 Cr | -13.31 | |
| Mar2022 | ₹8,960 Cr | 28.56 | |
| Mar2021 | ₹6,969 Cr | 29.20 | |
| Mar2020 | ₹5,394 Cr | - | |
DIVIS LABORATORIES Operating Profit
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | -6.88 % |
| 5 Yr CAGR | 4.88 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹2,206 Cr | -6.88 | |
| Mar2023 | ₹2,369 Cr | -38.96 | |
| Mar2022 | ₹3,881 Cr | 35.65 | |
| Mar2021 | ₹2,861 Cr | 56.92 | |
| Mar2020 | ₹1,823 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -7.80 % |
| 5 Yr CAGR | -4.50 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 28.12% | -7.80 | |
| Mar2023 | 30.5% | -29.59 | |
| Mar2022 | 43.32% | 5.53 | |
| Mar2021 | 41.05% | 21.45 | |
| Mar2020 | 33.8% | - | |
DIVIS LABORATORIES Profit After Tax
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | -12.28 % |
| 5 Yr CAGR | 3.83 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,600 Cr | -12.28 | |
| Mar2023 | ₹1,824 Cr | -38.39 | |
| Mar2022 | ₹2,960 Cr | 49.19 | |
| Mar2021 | ₹1,984 Cr | 44.15 | |
| Mar2020 | ₹1,377 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -13.07 % |
| 5 Yr CAGR | -5.31 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 20.28 % | -13.07 | |
| Mar2023 | 23.33 % | -29.17 | |
| Mar2022 | 32.94 % | 16.07 | |
| Mar2021 | 28.38 % | 12.49 | |
| Mar2020 | 25.23 % | - | |
DIVIS LABORATORIES Earnings Per Share (EPS)
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | -12.28 % |
| 5 Yr CAGR | 3.88 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹60 | -12.28 | |
| Mar2023 | ₹69 | -38.29 | |
| Mar2022 | ₹112 | 49.20 | |
| Mar2021 | ₹75 | 44.14 | |
| Mar2020 | ₹52 | - | |
DIVIS LABORATORIES Return on Capital Employed (ROCE)
[BOM: 532488|NSE : DIVISLAB]
| Y-o-Y | -14.98 % |
| 5 Yr CAGR | -10.24 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 16.46% | -14.98 | |
| Mar2023 | 19.36% | -44.78 | |
| Mar2022 | 35.06% | 9.32 | |
| Mar2021 | 32.07% | 26.46 | |
| Mar2020 | 25.36% | - | |
DIVIS LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹6,833.1 |
| Current MarketCap | : | ₹ 181,418.8 Cr |
| Updated EOD on | : | Jul 11,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | -0.7% |
1.6% |
50.2% |
| SENSEX | -1.1% |
-0% |
3.2% |
DIVIS LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE DIVIDEND STABILITY INDEX | -0.9% | -0.7% | -7% |
| BSE 500 | -1.1% | -0.2% | 0.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 EQUAL WEIGHT | -0.7% | -0.3% | -0.3% |
| NIFTY PHARMA | -0.7% | 0.8% | 9.4% |
| NIFTY GROWTH SECTORS 15 | -0.8% | 0.6% | 1.3% |
| NIFTY ALPHA QUALITY LOW-VOLATILITY 30 | -0.9% | -0.5% | -6.7% |
| NIFTY NEXT 50 | -0.9% | -1.2% | -7.5% |
You may also like the below Video Courses
FAQ about DIVIS LABORATORIES Financials
How the annual revenues of DIVIS LABORATORIES have changed ?
The Revenues of DIVIS LABORATORIES have increased by 1.00% YoY .
How the Earnings per Share (EPS) of DIVIS LABORATORIES have changed?
The Earnings Per Share (EPS) of DIVIS LABORATORIES has decreased by -12.28 % YoY .
Check out Intrinsic Value of Peers of DIVIS LABORATORIES
Compare Stock Analytics of Peers of DIVIS LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
